Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Breakthrough Designation Can Be 'Lever' For Manufacturing Evolution, FDA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

CDER Director Woodcock notes breakthrough program often pushes sponsors to modernize production processes.

You may also be interested in...

Breakthrough In Two Pages: FDA Offers Preliminary Advice

Agency now allows sponsors of potential breakthrough therapies to request preliminary advice, but sponsors may not necessarily want to use it.

PDUFA Negotiations: Early Communications, Breakthrough Still On Docket

FDA and industry also talking about improvements to combination product review process as part of user fee program renewal.

Breakthrough Requests: FDA Adds Quick Screen To Pare Workload

Hope is to quickly reject obviously inadequate designation requests, but few meet criteria for dismissal so far.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts